Biotech Nkarta Strengthens Executive Team with Major Equity Package for R&D Chief

Rhea-AI Filing Summary

Nkarta reported a significant insider transaction involving Chief Medical Officer and Head of R&D, Shawn Marshall Rose. On June 23, 2025, Rose was granted stock options to purchase 500,000 shares of common stock at an exercise price of $1.75 per share.

The stock options have a structured vesting schedule:

• 25% of the options vest on July 23, 2026
• Remaining 75% vest in 36 equal monthly installments following June 23, 2026
• Options expire on June 22, 2035

This grant suggests a long-term retention strategy for a key executive, with the low exercise price potentially indicating recent stock price challenges or an incentive-focused compensation structure. The substantial size of the grant (500,000 shares) reflects the senior leadership position and importance of the R&D function to the company.

Positive

• Chief Medical Officer received a significant stock option grant of 500,000 shares at $1.75 exercise price, representing strong long-term alignment with shareholders

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rose Shawn Marshall

(Last) (First) (Middle)

1150 VETERANS BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nkarta, Inc. [ NKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.75	06/23/2025		A		500,000		(1)	06/22/2035	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. The option is scheduled to vest and become exercisable as to 25% of the shares subject to the grant on July 23, 2026. The remaining portion of the option is scheduled to vest and become exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 23, 2026.

Remarks:

Chief Medical Officer, Head of Research & Development

	/s/ Bridgette Housley, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did NKTX's Chief Medical Officer receive on June 23, 2025?

NKTX's Chief Medical Officer, Shawn Marshall Rose, received 500,000 stock options with an exercise price of $1.75 per share on June 23, 2025.

What is the vesting schedule for NKTX CMO's stock options granted in June 2025?

The stock options vest over 4 years, with 25% vesting on July 23, 2026, and the remaining 75% vesting in 36 equal monthly installments following June 23, 2026.

What is the expiration date for NKTX CMO's stock options granted in June 2025?

The stock options granted to NKTX's Chief Medical Officer expire on June 22, 2035, ten years after the grant date.

What is the exercise price of the stock options granted to NKTX's CMO in June 2025?

The exercise price of the stock options granted to NKTX's Chief Medical Officer is $1.75 per share.

Who is NKTX's Chief Medical Officer and Head of Research & Development as of June 2025?

Shawn Marshall Rose serves as NKTX's Chief Medical Officer and Head of Research & Development, based at 1150 Veterans Blvd, South San Francisco, CA.